New York, NY -- (SBWIRE) -- 12/24/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Synthetic Biologics Inc (NYSEMKT:SYN), Synergy Pharmaceuticals Inc (NASDAQ:SGYP), Array Biopharma Inc (NASDAQ:ARRY), Renren Inc (NYSE:RENN)
Synthetic Biologics Inc (NYSEMKT:SYN) showed a volume of 1.75 million shares by the end of last trade whereas the average volume of the stock remained 387,618.00 shares. The stock opened the session at $1.22 but then moved to $1.73. At that price, the stock showed a positive performance of 18.10%. Synthetic Biologics, Inc., formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development of synthetic deoxyribonucleic acid (DNA)-based therapeutics and disease-modifying medicines for serious illnesses. Its initial synthetic biologic product candidate is intended to treat pulmonary arterial hypertension (PAH) by delivering therapeutic DNA to the lungs of PAH patients and controlling long-term expression of such DNA via an oral daily pill.
Will SYN Continue To Move Higher? Find Out Here
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) opened the session at $4.44 and closed the session at $4.69. The stock showed a positive performance of 8.56% in previous trading session. Traded with volume of 1.63 million shares in the prior session and the average volume of the stock remained 374,201.00 shares. Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company’s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C).
For How Long SGYP will fight for Profitability? Read This Trend Analysis report
Array Biopharma Inc (NASDAQ:ARRY) opened the session at $4.88 and closed the session at $4.81. The stock showed a negative performance of -0.82% in previous trading session. Traded with volume of 1.41 million shares in the prior session and the average volume of the stock remained 1.75 million shares. The beta of the stock remained 1.61. Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. The Company’s drug candidates include AMG 151, MEK162, ARRY-380, ARRY-520, ARRY-543 and ARRY-614.
Why Should Investors Buy ARRY After the Recent Fall? Just Go Here and Find Out
Renren Inc (NYSE:RENN) the stock advanced 1.00% and finished the session at $3.02. Traded with volume of 1.30 million shares in the prior session and the average volume of the stock remained 2.33 million shares. Renren Inc. operates real name social networking Internet platform in the People’s Republic of China. Its platform enables its users to connect and communicate with each other, share information and user-generated content, play online games, listen to music, shop for deals and a range of other features and services. Its Renren Open Platform program allows users to access applications from third-party developers through an open application programming interface. Its Renren Connect program allows users to sign in and share information and content from over 2,000 Renren Connect partner Websites.
Will RENN Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)